After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...